Category: Tuberculosis
| Intervention | Condition | Outcome / Effect | Source | ||
|---|---|---|---|---|---|
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST (standardiz |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Implementing second-line DST for all patients with rifampin-resistant tuberculosis could substantial
Not specified (qualitative: 'substantial |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST (standardiz |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Implementing second-line DST for all patients with rifampin-resistant tuberculosis could reduce tran
Not specified (qualitative: 'reduce tran |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST (standardiz |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Implementing second-line DST for all patients with rifampin-resistant tuberculosis could prevent amp
Not specified (qualitative: 'prevent amp |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST (standardiz |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Implementing second-line DST for all patients with rifampin-resistant tuberculosis could be affordab
Not specified (qualitative: 'be affordab |
↑ | 5576040 |
| 📊 |
Standardized treatment regimens
vs Individualized regimens based |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Standardized treatment regimens without second-line DST reduce the probability of treatment success
Not specified (qualitative: 'reduce the |
↓ | 5576040 |
| 📊 |
Standardized treatment regimens
vs Individualized regimens based |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Standardized treatment regimens without second-line DST expose patients to toxicity without benefit.
Not specified (qualitative: 'expose pati Side effects: Toxicity without benefit |
↓ | 5576040 |
| 📊 |
Standardized treatment regimens
vs Individualized regimens based |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Standardized treatment regimens without second-line DST amplify drug resistance in rifampin-resistan
Not specified (qualitative: 'amplify dru Side effects: Amplification of drug resistance |
↓ | 5576040 |
| 📊 |
Number of effective drugs in
vs Regimens with fewer effective |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Each additional effective drug in the regimen increases the probability of treatment success in rifa
Each additional effective drug increases |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Second-line DST enables rapid identification of appropriate candidates for the 9-month regimen for r
Not specified (qualitative: 'rapidly ide |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Second-line DST represents a small incremental cost (about 2% of total treatment cost per patient) i
Second-line DST cost is about 2% of tota |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Implementing second-line DST for all patients with rifampin-resistant tuberculosis faces significant
Not specified (qualitative: 'logistical |
— | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Where second-line DST has been implemented with effective regimens and public health efforts, drug-r
Not specified (qualitative: 'epidemics h |
↑ |
5576040
A few years |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Second-line DST increases the number of effective drugs in each regimen for rifampin-resistant tuber
Not specified (qualitative: 'increase th |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs No second-line DST |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Second-line DST enables more rapid initiation of effective therapy for rifampin-resistant tuberculos
Not specified (qualitative: 'rapidly ini |
↑ | 5576040 |
| 📊 |
Second-line drug susceptibility testing
vs Not specified |
Multidrug-Resistant Tuberculosis
Rifampin-resistant tuberculosi |
Among patients with baseline resistance to 3 or more second-line drugs, 44% acquired XDR during trea
44% of patients with baseline resistance Side effects: Acquisition of XDR TB |
↑ |
5576040
During treatment |
| 📊 | Standardized MDR TB treatment | Multidrug-Resistant Tuberculosis
Adults |
A decentralised model of care for MDR-TB patients in South Africa resulted in a cure rate of 51% as
51% of patients enrolled were cured |
↑ |
3005763
24 months |
| 📊 | Decentralised model of care for multidru | Multidrug-Resistant Tuberculosis
Adults |
A decentralised model of care for MDR-TB patients in South Africa resulted in a cure rate of 51% as
51% of patients enrolled were cured |
↑ |
3005763
24 months |
| 📊 | Standardized MDR TB treatment | Multidrug-Resistant Tuberculosis
Adults |
In the decentralised model of care for MDR-TB, 15% of patients had their clinical notes lost during
15% of patients' notes were lost (226 of |
↓ |
3005763
24 months |
| 📊 | Decentralised model of care for MDR-TB | Multidrug-Resistant Tuberculosis
Adults |
In the decentralised model of care for MDR-TB, 15% of patients had their clinical notes lost during
15% of patients' notes were lost (226 of |
↓ |
3005763
24 months |
| 📊 |
Standardized MDR TB treatment
vs ART initiation within 1 month |
Multidrug-Resistant Tuberculosis
Adults |
Delayed initiation of ART (7 months after MDR-TB treatment start instead of within 1 month) resulted
ART started 7 months after MDR-TB treatm |
↓ |
3005763
24 months |
| 📊 |
Delayed initiation of antiretroviral the
vs ART initiation within 1 month |
Multidrug-Resistant Tuberculosis
Adults |
Delayed initiation of ART (7 months after MDR-TB treatment start instead of within 1 month) resulted
ART started 7 months after MDR-TB treatm |
↓ |
3005763
24 months |
| 📊 | Standardized MDR TB treatment | Multidrug-Resistant Tuberculosis
Adults |
A public workers’ strike led to 2 months of missed treatment visits (no treatment received) for MDR-
2 months of missed treatment due to stri |
↓ |
3005763
24 months |
| 📊 | Public workers’ strike | Multidrug-Resistant Tuberculosis
Adults |
A public workers’ strike led to 2 months of missed treatment visits (no treatment received) for MDR-
2 months of missed treatment due to stri |
↓ |
3005763
24 months |
| 📊 |
Standardized MDR TB treatment
vs No stock-out (full regimen) |
Multidrug-Resistant Tuberculosis
Adults |
Stock-outs of ofloxacin and ethambutol led to incomplete drug regimens (four drugs instead of five)
Four drugs dispensed instead of five dur |
↓ |
3005763
24 months |
| 📊 |
Drug stock-outs
vs No stock-out (full regimen) |
Multidrug-Resistant Tuberculosis
Adults |
Stock-outs of ofloxacin and ethambutol led to incomplete drug regimens (four drugs instead of five)
Four drugs dispensed instead of five dur |
↓ |
3005763
24 months |
| 📊 | Standardized MDR TB treatment | Multidrug-Resistant Tuberculosis
Adults |
Socio-economic barriers such as impassable roads and lack of transport money led to missed treatment
Missed visits in months 15 and 21 due to |
↓ |
3005763
24 months |
| 📊 |
Standardized MDR TB treatment
vs Adapted regimen (with ethambut |
Multidrug-Resistant Tuberculosis
Adults |
Loss of clinical notes during treatment led to the issuance of a standardised regimen instead of an
Standardised regimen issued despite need |
↓ |
3005763
24 months |
| 📊 |
Loss of clinical notes during
vs Adapted regimen (with ethambut |
Multidrug-Resistant Tuberculosis
Adults |
Loss of clinical notes during treatment led to the issuance of a standardised regimen instead of an
Standardised regimen issued despite need |
↓ |
3005763
24 months |
| 📊 |
Greater baseline resistance
vs Optimal treatment (full treatm |
Multidrug-Resistant Tuberculosis
Adults |
A patient who received full treatment for only 42% of the time, incomplete treatment for 42%, and no
Patient received full treatment for 42% |
— |
3005763
24 months |
| 📊 |
Sub-optimal
vs Optimal treatment (full treatm |
Multidrug-Resistant Tuberculosis
Adults |
A patient who received full treatment for only 42% of the time, incomplete treatment for 42%, and no
Patient received full treatment for 42% |
— |
3005763
24 months |
| 📊 |
Prior TB
vs No health system obstacles |
Multidrug-Resistant Tuberculosis
Adults |
Health system obstacles such as fragmentation of care, irregular drug supplies, inappropriate regime
Increased chances of unsuccessful treatm |
↓ | 3005763 |
| 📊 |
Health system obstacles
vs No health system obstacles |
Multidrug-Resistant Tuberculosis
Adults |
Health system obstacles such as fragmentation of care, irregular drug supplies, inappropriate regime
Increased chances of unsuccessful treatm |
↓ | 3005763 |
| 📊 |
Diagnosis in years 2001, 2002, or 2003
vs No quality improvement program |
Multidrug-Resistant Tuberculosis
Adults |
Implementation of a facility-level quality improvement programme focusing on patient-centred care, a
Facility-level resolution of many proble |
↑ | 3005763 |
| 📊 |
Facility-level quality improvement progr
vs No quality improvement program |
Multidrug-Resistant Tuberculosis
Adults |
Implementation of a facility-level quality improvement programme focusing on patient-centred care, a
Facility-level resolution of many proble |
↑ | 3005763 |
| 📊 |
HIV co-infection
vs HIV-negative |
Multidrug-Resistant Tuberculosis
MDR TB patients |
HIV co-infection increased the risk of treatment default among MDR TB patients.
AOR 2.0 |
↓ |
3005763
up to 2 years |
| 📊 |
Male sex hormones borderline
vs Female sex |
Multidrug-Resistant Tuberculosis
MDR TB patients |
Male sex increased the risk of treatment default among MDR TB patients.
AOR 1.9 |
↓ |
3005763
up to 2 years |
| 📊 |
HIV co-infection
vs HIV-negative |
Multidrug-Resistant Tuberculosis
MDR TB patients |
HIV co-infection was not a significant risk factor for treatment failure among MDR TB patients in mu
Not significant in multivariate analysis |
— |
3005763
up to 2 years |
| 📊 |
Imputation of HIV status
vs No imputation |
Multidrug-Resistant Tuberculosis
MDR TB patients |
Imputation of HIV status for missing data did not significantly affect the association between HIV a
No significant change in effect size or |
— |
3005763
up to 2 years |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
In children with MDR-TB in Georgia treated with second-line anti-tuberculosis medications, 77.1% ach
77.1% (95% CI 61.0–87.9) Side effects: No data collected on adverse events |
↑ |
3734931
Median 20.5 months ( |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB in Georgia treated with second-line anti-tuberculosis medications, 20.0%
20.0% Side effects: No data collected on adverse events |
↓ |
3734931
Median 20.5 months |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB in Georgia treated with second-line anti-tuberculosis medications, 2.9% d
2.9% Side effects: No data collected on adverse events |
↓ |
3734931
Median 20.5 months |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB or DR-TB in Georgia, 97.6% were culture positive at baseline before start
97.6% culture positive (41/42) |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB or DR-TB in Georgia, 70.5% had extra-pulmonary TB (EPTB) at baseline.
70.5% (31/44) had EPTB |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Just over half of the children with MDR-TB or DR-TB in Georgia had received previous TB treatment be
51% had previous TB treatment |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
The median time from diagnosis to treatment initiation with second-line anti-tuberculosis medication
Median 16 days (range 0–311) |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
The median number of medications used per child with MDR-TB or DR-TB in Georgia was 6 (range 4–9).
Median 6 (range 4–9) |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB or DR-TB in Georgia, 97.8% received an injectable agent for at least 6 mo
97.8% (44/45) received injectable agent |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB or DR-TB in Georgia, 93.3% received a fluoroquinolone as part of second-l
93.3% (42/45) received fluoroquinolone |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB or DR-TB in Georgia, 58% were tested for HIV.
58% tested for HIV |
— | 3734931 |
| 📊 | Second-line anti-tuberculosis medication | Multidrug-Resistant Tuberculosis
Children |
Among children with MDR-TB or DR-TB in Georgia who were tested for HIV, none were HIV positive.
0% HIV positive (0/19 tested) |
— | 3734931 |
| 📊 | MDR-TB treatment initiation among preval | Multidrug-Resistant Tuberculosis
Global TB patients |
Only 20% of MDR-TB cases among prevalent TB patients had access to MDR-TB treatment in 2014.
20% |
— | 5381649 |
| 📊 | MDR-TB treatment initiation among notifi | Multidrug-Resistant Tuberculosis
Global TB patients |
37% of MDR-TB cases among notified TB patients had access to MDR-TB treatment in 2014.
37% |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
Global TB patients |
MDR-TB treatment was successful in only 50% of those who started treatment in 2012.
50% |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
Global TB patients |
Only 10% of MDR-TB cases among prevalent TB patients are expected to be successfully treated.
10% |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
Global TB patients |
Only 11.5% of MDR-TB cases among incident TB patients are expected to be successfully treated.
11.5% |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
Global TB patients |
Only 18.5% of MDR-TB cases among notified TB patients are expected to be successfully treated.
18.5% |
— | 5381649 |
| 📊 | Routine drug susceptibility testing cove | Multidrug-Resistant Tuberculosis
European TB patients |
In Europe, 97% of new and 52% of previously treated TB patients had DST results.
97% (new), 52% (previously treated) |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
African TB patients |
In Africa, nearly 80% of MDR-TB cases estimated to have occurred among notified TB patients were rep
80% (of estimated MDR-TB among notified |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
European TB patients |
In Europe, 59% of estimated MDR-TB cases among notified patients and 40% of estimated MDR-TB cases a
59% (notified), 40% (prevalent) |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
Global TB patients |
Only 23% of estimated, incident MDR-TB patients in a year start treatment.
23% |
— | 5381649 |
| 📊 | MDR-TB | Multidrug-Resistant Tuberculosis
Global TB patients |
Treatment of MDR-TB lasts approximately 18–24 months.
18–24 months |
— | 5381649 |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
MDR-TB treatment resulted in a mean of 8.6 adverse drug reactions (ADRs) per patient as reported by
mean 8.6 ADRs per patient |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
MDR-TB treatment resulted in a mean of 1.4 adverse drug reactions (ADRs) per patient as documented i
mean 1.4 ADRs per patient |
↓ |
4830122
not applicable |
| 📊 |
Video recording of patient interview
vs clinician documentation (medic |
Multidrug-Resistant Tuberculosis
MDR-TB patients |
Patients reported significantly more ADRs (mean 8.6) than were documented in the medical record (mea
t(120) = 19.06, p < 0.001 |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
67% of MDR-TB patients reported insomnia as an ADR during treatment in patient interviews.
67% |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
2% of MDR-TB patients had insomnia documented as an ADR in the medical record during treatment.
2% |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
65% of MDR-TB patients reported peripheral neuropathy as an ADR during treatment in patient intervie
65% |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
18% of MDR-TB patients had peripheral neuropathy documented as an ADR in the medical record during t
18% |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
61% of MDR-TB patients reported confusion or trouble remembering as an ADR during treatment in patie
61% |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
4% of MDR-TB patients had confusion or trouble remembering documented as an ADR in the medical recor
4% |
↓ |
4830122
not applicable |
| 📊 |
patient interview vs. clinician document
vs clinician documentation (medic |
Multidrug-Resistant Tuberculosis
MDR-TB patients |
For all ADRs except hearing loss, there was a significant difference between patient-reported and cl
p < 0.001 for all ADRs except hearing lo |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
72% of MDR-TB patients who reported arthralgia as an ADR rated it as 'bothers me a lot' (level 4 sev
72% reported 'bothers me a lot' (level 4 |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
69% of MDR-TB patients who reported insomnia as an ADR rated it as 'bothers me a lot' (level 4 sever
69% reported 'bothers me a lot' (level 4 |
↓ |
4830122
not applicable |
| 📊 | Multidrug-Resistant Tuberculosis | Multidrug-Resistant Tuberculosis
MDR-TB patients |
62% of MDR-TB patients who reported changes in vision as an ADR rated it as 'bothers me a lot' (leve
62% reported 'bothers me a lot' (level 4 |
↓ |
4830122
not applicable |
| 📊 |
HIV status
vs non-HIV-infected MDR-TB patien |
Multidrug-Resistant Tuberculosis
MDR-TB patients |
There was no significant difference in the total number of ADRs reported by patient interview betwee
U = 1.09, p = 0.277 |
— |
4830122
not applicable |
| 📊 |
HIV status
vs non-HIV-infected MDR-TB patien |
Multidrug-Resistant Tuberculosis
MDR-TB patients |
There was no significant difference in the total number of ADRs documented in the medical record bet
U = 1.66, p = 0.098 |
— |
4830122
not applicable |
| 📊 |
pH-sensitive, ratiometric GFP Mtb report
vs no conversion at 6 months |
Multidrug-Resistant Tuberculosis
Tuberculosis patients |
Culture conversion at 6 months in MDR-TB is significantly associated with treatment success compared
adjusted OR 14.07; sensitivity 92%, spec |
↑ | 6354243 |
| 📊 |
Culture conversion at 6 months
vs no conversion at 6 months |
Multidrug-Resistant Tuberculosis
Tuberculosis patients |
Culture conversion at 6 months in MDR-TB is significantly associated with treatment success compared
adjusted OR 14.07; sensitivity 92%, spec |
↑ | 6354243 |
| 📊 |
granuloma structure
vs no conversion at 2 months |
Multidrug-Resistant Tuberculosis
Tuberculosis patients |
Culture conversion at 2 months in HIV-uninfected MDR-TB patients is significantly associated with su
adjusted OR 4.12 |
↑ | 6354243 |
| 📊 |
Trimethoprim-Sulfamethoxazole Combinatio
vs no conversion at 2 months |
Multidrug-Resistant Tuberculosis
Tuberculosis patients |
Culture conversion at 2 months in HIV-uninfected MDR-TB patients is significantly associated with su
adjusted OR 4.12 |
↑ | 6354243 |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment did not significantly increase the frequency of adverse events c
90.9% of drinkers vs. 88.9% of non-drink Side effects: Most frequent: gastrointestinal (78%), arthralgia |
— |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment was associated with a lower likelihood of favourable treatment o
OR 0.28 |
↓ |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment was associated with increased risk of death during treatment com
P < 0.0001 (direction: increased death) |
↓ |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment was associated with increased risk of default from treatment com
P < 0.05 (direction: increased default) |
↓ |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
After adjusting for adherence, alcohol use during MDR-TB treatment remained negatively associated wi
Adjusted OR 0.38 |
↓ |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment was not significantly associated with earlier time to default fr
Mean 230 b1 124 days (drinkers) vs. 248 |
— |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment was not significantly associated with increased risk of hepatoto
No significant difference at elevations Side effects: Hepatotoxicity rates not increased in drinkers |
— |
8324013
Not specified |
| 📊 |
Alcohol use during MDR-TB
vs No alcohol use during MDR-TB t |
Multidrug-Resistant Tuberculosis
Adults |
Alcohol use during MDR-TB treatment was not significantly associated with increased permanent interr
No significant difference between drinke |
— |
8324013
Not specified |
| 📊 |
Adherence to at least 80% of prescribed
vs Less than 80% adherence |
Multidrug-Resistant Tuberculosis
Adults |
Among drinkers, adherence to at least 80% of prescribed doses was associated with higher odds of fav
OR 2.89 |
↑ |
8324013
Not specified |
| 📊 |
Interruption of treatment due to adverse
vs No interruption due to adverse |
Multidrug-Resistant Tuberculosis
Adults |
Among drinkers, interruption of treatment due to an adverse event was associated with higher odds of
OR 2.49 |
↓ |
8324013
Not specified |
| 📊 |
Diagnosis of alcoholism at baseline
vs No diagnosis of alcoholism at |
Multidrug-Resistant Tuberculosis
Adults |
Among drinkers, a diagnosis of alcoholism at baseline was associated with worse treatment outcomes.
Direction: worse outcome (no OR reported |
↓ |
8324013
Not specified |
The standard treatment for drug-resistant tuberculosis (specifically multidrug-resistant TB, MDR-TB) involves individualized regimens guided by second-line drug susceptibility testing (DST), which substantially improves treatment outcomes compared to standardized regimens without DST. (5576040) Second-line DST enables rapid identification of appropriate candidates for the 9-month regimen and allows for more rapid initiation of effective therapy in rifampin-resistant TB. (5576040) Standardized treatment regimens without second-line DST reduce the probability of treatment success and can expose patients to toxicity without benefit. (5576040) Each additional effective drug in the regimen increases the probability of treatment success, with fluoroquinolones increasing success rates threefold, second-line injectables twofold, and pyrazinamide twofold. (5576040)